Global Regulatory Intelligence
Log in |  Register

Login to your account

Username *
Password *
Remember Me

Create an account

Registering to our Regulatory Updates easy andis should only
take few minutes. To begin, enter your email enter your email
address below so we can check to see if it is already existing
in our records. Your email address will also be used as your
user name when you log in.

Fields marked with an asterisk (*) are required.
Name *
Username *
Password *
Verify password *
Email *
Verify email *
Captcha *
Reload Captcha

USA: FDA Releases Guidance on Systemic Antibacterial Drugs

Wednesday, February 07, 2018: The US Food and Drug Administration (FDA) published guidance on the development, analysis, and presentation of microbiology data during the development of antibacterial drugs. The agency discusses the overall microbiology development program it says is needed to support clinical development and approval of antibacterial drugs administered systemically. The guidance also addresses microbiology data collected after drug approval.

The new guidance replaces Microbiology Data for Systemic Antibacterial Drugs—Development, Analysis, and Presentation, which was published in August 2016. FDA changed the presentation of microbiology data. This change was required by section 3044 of the 21st Century Cures Act, which added section 511A to the Federal Food, Drug, and Cosmetic Act (FD&C Act). This new section created new processes for susceptibility test interpretive criteria recognition. FDA is required to make changes, including establishing a web page for susceptibility test interpretive criteria and changes to the labeling for antibacterial and antifungal drugs on susceptibility test interpretive criteria.

More Details
© 2016 MakroCare. All Rights Reserved.
  Privacy policy